Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. [electronic resource]
Producer: 20000824Description: 3761-9 p. digitalISSN:- 0008-5472
- Animals
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Agents, Alkylating -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Body Weight -- drug effects
- Cell Division -- drug effects
- Cyclophosphamide -- administration & dosage
- Cytochrome P-450 Enzyme System -- metabolism
- Dose-Response Relationship, Drug
- Gene Transfer Techniques
- Genetic Vectors
- Gliosarcoma -- drug therapy
- Humans
- Hypoxia
- Mice
- Mice, SCID
- NADH, NADPH Oxidoreductases -- metabolism
- NADPH-Ferrihemoprotein Reductase
- Neoplasm Transplantation
- Oxygen -- metabolism
- Prodrugs -- pharmacology
- Retroviridae -- metabolism
- Time Factors
- Tirapazamine
- Transduction, Genetic
- Triazines -- administration & dosage
- Tumor Cells, Cultured
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.